MNKD
NASDAQMannKind Corporation
Price$3.63+0.03 (+0.83%)
01:30 PM07:45 PM
News · 26 weeks69+46%
2025-12-142026-06-07
Mix4190d
- Insider22(54%)
- Other9(22%)
- SEC Filings7(17%)
- Earnings3(7%)
Latest news
25 items- PRData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) SystemsBuilds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfactionExploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithmsData from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic dis
- PRMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFPhase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and support its progression into mid-stage clinica
- SECMannKind Corporation filed SEC Form 8-K: Other Events8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions
- PRMannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with DiabetesEnables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the dayApproval advances pediatric diabetes care by introducing a new inhaled mealtime insulin option recognized in the American Diabetes Association (ADA) Standards of Care alongside multiple daily injections (MDI) and insulin pumpsApproval is supported by results from the Phase 3 INHALE-1 study in pediatric patients, along with clinical efficacy and safety evidence generated across thousands of patients over the past 20+ years of Technosphere® inhaled insulin developmentEligible patients can access Afrezza today for $35 or less per month, with
- SECMannKind Corporation filed SEC Form 8-K: Other Events8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind to Present at Jefferies Global Healthcare ConferenceDANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET. Links to the live audio webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company dedicated to transforming chronic disea
- PRMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) SystemsNew analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancyLate-breaking comparative data vs. rapid-acting insulin analogs to be presented June 7Nine posters showcase new clinical and real-world insights across dosing approaches, glycemic control, and patient-reported experience PDUFA target action date for Afrezza in children and adolescents living with diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative
- INSIDERSEC Form 4 filed by Director Friedman Michael A4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Consiglio Ronald J was granted 10,000 shares, increasing direct ownership by 8% to 132,342 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Binder Steven B.4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Grancio Jennifer4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Hooper Anthony C4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Shannon James Samuel4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief People & Workpl Officer Tross Stuart A was granted 33,898 shares, increasing direct ownership by 3% to 1,026,122 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERPres, Endocrine Business Unit Marasco Dominic was granted 8,474 shares, increasing direct ownership by 3% to 344,246 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Mundkur Christine4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Kay Sabrina4 - MANNKIND CORP (0000899460) (Issuer)
- SECMannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MANNKIND CORP (0000899460) (Filer)
- INSIDERChief People & Workpl Officer Tross Stuart A covered exercise/tax liability with 8,073 shares, decreasing direct ownership by 0.81% to 992,224 units (SEC Form 4) to cover taxes4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Executive Officer Castagna Michael covered exercise/tax liability with 34,957 shares, decreasing direct ownership by 1% to 2,442,310 units (SEC Form 4) (for withholding tax)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Binder Steven B. covered exercise/tax liability with 5,560 shares and sold $55,733 worth of shares (16,940 units at $3.29), decreasing direct ownership by 3% to 808,008 units (SEC Form 4) to satisfy tax liability4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDEREVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 12,387 shares and sold $9,979 worth of shares (3,033 units at $3.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 826,299 units (SEC Form 4) to satisfy withholding tax4 - MANNKIND CORP (0000899460) (Issuer)
- SECSEC Form SCHEDULE 13G filed by MannKind CorporationSCHEDULE 13G - MANNKIND CORP (0000899460) (Subject)
- PRThe $59B Quiet Shift Reshaping How Patients Access CareIssued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and
MNKD FAQ
7 questionsWhat does MannKind Corporation do?
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary...Where does MNKD stock trade?
MannKind Corporation (MNKD) is listed on NASDAQ.What sector and industry is MNKD in?
MannKind Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MannKind Corporation go public?
MannKind Corporation (MNKD) completed its IPO in 2004.What are analysts saying about MNKD?
MannKind Corporation has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform with a $350.00 price target on 2026-02-27. Recent price targets range from $350.00 to $1200.00.What companies are similar to MNKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MNKD side-by-side with any of them on Quantisnow.How can I track MNKD on Quantisnow?
Quantisnow aggregates MannKind Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNKD to receive live email and push alerts on every new disclosure.